Carregant...
Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity
Immune checkpoint inhibitors (ICIs) targeting programmed death‐1 (PD‐1), its ligand (PD‐L1), and cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA4) have revolutionized cancer treatment by recovering the attack of T lymphocytes on the malignant cells. They have improved clinical outcomes dramaticall...
Guardat en:
| Publicat a: | Thorac Cancer |
|---|---|
| Autors principals: | , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley & Sons Australia, Ltd
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6996973/ https://ncbi.nlm.nih.gov/pubmed/31849171 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13250 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|